Cardiology Xagena
The presentation of the PLATO ( A Study of Platelet Inhibition and Patient Outcomes ), showed that Ticagrelor ( Brilinta ) reduced the rate of cardiovascular events ( cardiovascular death, myocardial ...
American Heart Association ( AHA ) and American College of Cardiology ( ACC ) have updated the guideline for the management of patients with non–ST-elevation acute coronary syndromes ( NSTE-ACS ). T ...
The results of the phase IV ATLANTIC study, which indicates that the profile of Ticagrelor ( Brilinta, Brilique ) is comparable whether administered in a pre-hospital or in-hospital setting to ST segm ...
The results of a sub-analysis of the PEGASUS-TIMI 54 study, which evaluated reasons and rates for discontinuation of Ticagrelor ( Brilinta, Brilique ) in patients with a history of myocardial infarcti ...
The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. Researchers have investigated the efficacy and safety of Ticagrelor ( Brili ...
A sub-analysis of the PEGASUS-TIMI 54 study, assessing the effect of Ticagrelor ( Brilinta, Brilique ) in reducing atherothrombotic events in post-myocardial infarction patients, based on the time fro ...
Ticagrelor ( Brilinta, Brilique ) administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention ( PCI ), according to findings from the ATLANTIC-H24 ...
Major bleeding after acute coronary syndrome predicts a poor outcome but is challenging to define. The choice of antiplatelet influences bleeding risk. Major bleeding, subsequent myocardial infarct ...
